ICCC Immucell Corp.

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020
EN
06/10/2020

Underlying

ICCCImmucell Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immucell Corp.

 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turne...

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Com...

March 18, 2026 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Unaudited Financial Results for the Year Ended Dece...

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025 PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025. Management’s Discussion: “Today we are reporting 2025 net operating income of $1.6 million, an increase of $3.3 million compared to 2024. These results were largely driven by a signific...

March 4, 2026 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell to Announce Unaudited Financial Results for the Quarter and Y...

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ET PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026. The Company is planning to host a confere...

February 18, 2026 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Ful...

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Company expects...

January 8, 2026 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell to Conduct Conference Call with Investors to Discuss Strategi...

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and awa...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch